Search - tctmd.com

Displaying 261 - 280 of 286

Sort: Relevancy | Date

Presentation JIM 2019

12 months results of First-In-Man study with coronary dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LimC

Presenter: Robert J. Gil

February 15, 2019

Presentation JIM 2019

Unmet Clinical Needs With Current Drug-Eluting Stents

Presenter: Davide Capodanno

February 14, 2019

Presentation JIM 2019

Overall Experience of Abluminus DES in Real World and Dedicate Global Clinical Registry

Presenter: Luca Testa

February 14, 2019

Presentation JIM 2019

Cre8™ EVO: Turning PCI challenges of DM patients into today’s solution

Presenter: Didier Carrié

February 14, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Presentation

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

February 11, 2019

Podcast TCTMD Talking Points

ReCre8: A New Polymer-Free DES

February 06, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

Presentation ISET 2019

Current Options in the Management of Superficial Arterial Disease in 2019

Presenter: Gary Ansel

January 30, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Daily News

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Todd Neale

January 16, 2019

Presentation

Frequency of TVR With DCB vs Second-Generation DES for Coronary In-Stent Restenosis

January 15, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

News Daily News

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Michael O'Riordan

January 15, 2019

Podcast TCTMD Talking Points

DES for Femoropopliteal Disease: IMPERIAL

January 09, 2019

News Daily News

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Michael O'Riordan

January 08, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Advertisement

12 months results of First-In-Man study with coronary dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LimC

Unmet Clinical Needs With Current Drug-Eluting Stents

Overall Experience of Abluminus DES in Real World and Dedicate Global Clinical Registry

Cre8™ EVO: Turning PCI challenges of DM patients into today’s solution

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

ReCre8: A New Polymer-Free DES

Drug-Coated Therapy for ISR: Review of Options and Data

Current Options in the Management of Superficial Arterial Disease in 2019

5-Year Results from the IN.PACT SFA Randomized Trial

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Frequency of TVR With DCB vs Second-Generation DES for Coronary In-Stent Restenosis

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

DES for Femoropopliteal Disease: IMPERIAL

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content